BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 2150753)

  • 21. A role for Ras in v-Crk transformation.
    Greulich H; Hanafusa H
    Cell Growth Differ; 1996 Nov; 7(11):1443-51. PubMed ID: 8930393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The CDC42-specific inhibitor derived from ACK-1 blocks v-Ha-Ras-induced transformation.
    Nur-E-Kamal MS; Kamal JM; Qureshi MM; Maruta H
    Oncogene; 1999 Dec; 18(54):7787-93. PubMed ID: 10618719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Saccharomyces cerevisiae gene product SDC25 C-domain functions as an oncoprotein in NIH3T3 cells.
    Barlat I; Schweighoffer F; Chevallier-Multon MC; Duchesne M; Fath I; Landais D; Jacquet M; Tocque B
    Oncogene; 1993 Jan; 8(1):215-8. PubMed ID: 7999142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequent activation of non-ras transforming sequences in neoplastic Syrian hamster cells initiated with chemical carcinogens.
    Notario V; Castro R; Flessate DM; Doniger J; DiPaolo JA
    Oncogene; 1990 Sep; 5(9):1425-30. PubMed ID: 2216466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The defective transforming phenotype of c-Jun Ala(63/73) is rescued by mutation of the C-terminal phosphorylation site.
    Bost F; Caron L; Vial E; Montreau N; Marchetti I; Dejong V; Defize L; Castellazzi M; Binétruy B
    Oncogene; 2001 Nov; 20(50):7425-9. PubMed ID: 11704873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism of carcinogenesis: the role of oncogenes, transcriptional enhancers and growth factors.
    Spandidos DA
    Anticancer Res; 1985; 5(5):485-98. PubMed ID: 3904595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. R-Ras is regulated by activators and effectors distinct from those that control Ras function.
    Huff SY; Quilliam LA; Cox AD; Der CJ
    Oncogene; 1997 Jan; 14(2):133-43. PubMed ID: 9010215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological activity of human N-ras and K-ras genes containing the Asn17 dominant negative mutation.
    Kaplan JB
    Oncol Res; 1994; 6(12):611-5. PubMed ID: 7787254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of malignant growth potentials of v-Src-transformed human gallbladder epithelial cells by adenovirus-mediated dominant negative H-Ras.
    Tokumitsu Y; Nakano S; Ueno H; Niho Y
    J Cell Physiol; 2000 May; 183(2):221-7. PubMed ID: 10737897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. H-ras and raf-1 cooperate in transformation of NIH3T3 fibroblasts.
    Cuadrado A; Bruder JT; Heidaran MA; App H; Rapp UR; Aaronson SA
    Oncogene; 1993 Sep; 8(9):2443-8. PubMed ID: 8361757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-ras-transformed cloned rat embryo fibroblast cells.
    Su ZZ; Austin VN; Zimmer SG; Fisher PB
    Oncogene; 1993 May; 8(5):1211-9. PubMed ID: 8479744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. C127 cells resistant to transformation by tyrosine protein kinase oncogenes.
    Cuadrado A; Talbot N; Barbacid M
    Cell Growth Differ; 1990 Jan; 1(1):9-15. PubMed ID: 2150330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transformation of NIH/3T3 to anchorage independence by H-ras is accompanied by loss of suppressor activity.
    Tolsma SS; Cohen JD; Ehrlich LS; Bouck NP
    Exp Cell Res; 1993 Apr; 205(2):232-9. PubMed ID: 8482334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of transforming ras proteins containing leucine at position 61 by a new mouse monoclonal antibody, ras(53-69)Leu61.
    Bizub D; Fischberg-Bender E; Heimer EP; Felix A; Skalka AM
    Cancer Res; 1989 Nov; 49(22):6425-31. PubMed ID: 2680065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vav and Ras induce fibroblast transformation by overlapping signaling pathways which require c-Myc function.
    Katzav S; Packham G; Sutherland M; Aroca P; Santos E; Cleveland JL
    Oncogene; 1995 Sep; 11(6):1079-88. PubMed ID: 7566967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
    Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
    Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The p53 tumor suppressor gene and gene product.
    Levine AJ
    Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ornithine decarboxylase induction in transformation by H-Ras and RhoA.
    Shantz LM; Pegg AE
    Cancer Res; 1998 Jul; 58(13):2748-53. PubMed ID: 9661886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A dominant suppressive mutation in a cellular gene restores the nontransformed phenotype to v-fms-transformed mink cells.
    Kato J; Sherr CJ
    Oncogene; 1991 May; 6(5):687-93. PubMed ID: 2052353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SCH 51344 inhibits ras transformation by a novel mechanism.
    Kumar CC; Prorock-Rogers C; Kelly J; Dong Z; Lin JJ; Armstrong L; Kung HF; Weber MJ; Afonso A
    Cancer Res; 1995 Nov; 55(21):5106-17. PubMed ID: 7585559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.